A detailed history of Holocene Advisors, LP transactions in Denali Therapeutics Inc. stock. As of the latest transaction made, Holocene Advisors, LP holds 860,948 shares of DNLI stock, worth $18.7 Million. This represents 0.07% of its overall portfolio holdings.

Number of Shares
860,948
Holding current value
$18.7 Million
% of portfolio
0.07%

Shares

1 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 15, 2024

BUY
$15.83 - $23.35 $13.6 Million - $20.1 Million
860,948 New
860,948 $17.7 Million

Others Institutions Holding DNLI

About Denali Therapeutics Inc.


  • Ticker DNLI
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 134,174,000
  • Market Cap $2.92B
  • Description
  • Denali Therapeutics Inc., a biopharmaceutical company, discovers and develops therapeutic candidates for neurodegenerative diseases in the United States. It offers leucine-rich repeat kinase 2 (LRRK2) inhibitor product candidate, including BIIB122/DNL151, a small molecule inhibitor, which is in phase I and phase Ib clinical trials for the treatm...
More about DNLI
Track This Portfolio

Track Holocene Advisors, LP Portfolio

Follow Holocene Advisors, LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Holocene Advisors, LP, based on Form 13F filings with the SEC.

News

Stay updated on Holocene Advisors, LP with notifications on news.